Application of n-3 Fatty to Patient of Jaundice

CompletedOBSERVATIONAL
Enrollment

106

Participants

Timeline

Start Date

January 1, 2014

Primary Completion Date

October 1, 2017

Study Completion Date

October 15, 2017

Conditions
Obstructive JaundiceSurgical Procedure, Unspecified
Interventions
DRUG

trail cohort

"Drug: Omega-3 Fatty Acid-Based Parenteral Nutrition Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid \[FA\] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."

DRUG

control cohort

"Drug: Structolipid Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."

Trial Locations (1)

430030

Hepatic Surgery Center of Tongji Hospital, Wuhan

All Listed Sponsors
lead

Huazhong University of Science and Technology

OTHER

NCT03376945 - Application of n-3 Fatty to Patient of Jaundice | Biotech Hunter | Biotech Hunter